全福生技 6885
Listed · Biotechnology and medical care28.55▼-0.95 (-3.22%)After close
- Prev close
- 29.5
- Volume (shares)
- 575,521
- Data time
- 2026-11-12 13:30:00
- Open
- 29.10
- High
- 29.70
- Low
- 28.55
- Prev close
- 29.50
- Volume (lots)
- 576
- Turnover
- 0.17 億
- P/E
- —
- Cash yield
- —
Financial trends
Loading…
Consolidated statements; NT$100M (per-share items in NT$). Updated after each quarterly filing (MOPS). Some line items do not apply to financial companies.
Unit: 100 million TWD (EPS in TWD)Source: public data from MOPS, TWSE, TPEx and TDCC
Loading…
Figures are shown as announced, with no scoring or rating.
| Metric | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | -25.18% | -21.33% | -11.34% | -3.29% | -13.10% | 94.29% | 10.00% | 5.99% |
| Operating margin | -3,477.06% | -2,164.96% | -2,956.78% | -7,200.66% | -8,498.54% | -5,278.43% | -79,202.00% | -46,644.19% |
| Net margin | -3,337.38% | -3,224.73% | -2,691.99% | -6,655.44% | -7,135.64% | -7,695.24% | -69,893.00% | -42,209.36% |
| ROE (TTM) | -26.93% | -25.03% | -24.08% | -23.52% | -23.12% | -21.46% | -18.78% | -16.64% |
| ROA (TTM) | -27.38% | -23.96% | -22.42% | -21.28% | -22.31% | -19.47% | -17.01% | -15.06% |
| EPS, quarter (TWD) | -0.72 | -0.89 | -0.50 | -1.24 | -0.63 | -0.92 | -0.53 | -0.95 |
| EPS, TTM (TWD) | -3.35 | -3.26 | -3.29 | -3.32 | -2.93 | -2.84 | -2.63 | -2.70 |
| Month | Revenue | MoM | YoY | YTD | YTD YoY |
|---|---|---|---|---|---|
| 2026-10 | 0.0 | 19.64% | 74.85% | 0.1 | 205.15% |
| 2026-09 | 0.0 | 11.70% | 209.55% | 0.1 | 242.96% |
| 2026-08 | 0.0 | 31.47% | 157.11% | 0.1 | 248.26% |
| 2026-07 | 0.0 | -64.72% | 108.71% | 0.1 | 267.08% |
| 2026-06 | 0.0 | 189.29% | 491.54% | 0.1 | 305.07% |
| 2026-05 | 0.0 | 7.31% | -27.89% | 0.0 | 246.23% |
| 2026-04 | 0.0 | -36.38% | 2,152.94% | 0.0 | 2,578.36% |
| 2026-03 | 0.0 | 90.51% | 3,548.48% | 0.0 | 2,723.00% |
| 2026-02 | 0.0 | -35.97% | 1,758.82% | 0.0 | 2,316.42% |
| 2026-01 | 0.0 | -7.15% | 2,890.91% | 0.0 | 2,890.91% |
| 2025-12 | 0.0 | 56.55% | 3,121.21% | 0.1 | 1,548.65% |
| 2025-11 | 0.0 | -19.45% | 237.81% | 0.0 | 1,375.67% |
Revenue in NT$100M; 12 months per page.
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 |
| Operating expenses | 1.1 | 0.9 | 0.8 | 1.9 | 1.0 | 0.8 | 0.8 | 1.2 |
| Operating income | -1.1 | -0.9 | -0.8 | -1.9 | -1.0 | -0.8 | -0.8 | -1.2 |
| Non-operating items | 0.0 | -0.4 | 0.1 | 0.1 | 0.2 | -0.4 | 0.1 | 0.1 |
| Pre-tax income | -1.1 | -1.3 | -0.8 | -1.7 | -0.9 | -1.2 | -0.7 | -1.1 |
| Income tax | 0.0 | — | — | — | — | — | — | — |
| Continuing operations | -1.1 | -1.3 | -0.8 | -1.7 | -0.9 | -1.2 | -0.7 | -1.1 |
| Net income | -1.1 | -1.3 | -0.8 | -1.7 | -0.9 | -1.2 | -0.7 | -1.1 |
| Net income to parent | -1.0 | -1.2 | -0.7 | -1.6 | — | — | — | — |
| Net income to NCI | -0.1 | -0.1 | -0.1 | -0.1 | — | — | — | — |
| Other comprehensive income | -0.3 | 0.3 | 0.0 | -0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
| Total comprehensive income | -1.4 | -1.0 | -0.8 | -1.7 | -0.9 | -1.2 | -0.7 | -1.1 |
| EPS (TWD) | -0.72 | -0.89 | -0.50 | -1.24 | -0.63 | -0.92 | -0.53 | -0.95 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 9.8 | 10.5 | 11.2 | 12.1 | 13.3 | 17.0 | 18.3 | 18.8 |
| Non-current assets | 6.1 | 6.2 | 6.0 | 6.2 | 6.0 | 5.1 | 5.2 | 5.3 |
| Total assets | 15.8 | 16.6 | 17.3 | 18.3 | 19.3 | 22.1 | 23.5 | 24.1 |
| Current liabilities | 0.4 | 0.4 | 0.4 | 0.7 | 0.5 | 3.3 | 3.5 | 3.5 |
| Non-current liabilities | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Total liabilities | 0.5 | 0.4 | 0.5 | 0.7 | 0.6 | 3.3 | 3.5 | 3.5 |
| Share capital | 13.3 | 13.3 | 13.3 | 13.3 | 13.3 | 13.2 | 13.2 | 13.2 |
| Capital surplus | 10.3 | 10.0 | 13.6 | 13.6 | 13.6 | 13.3 | 16.3 | 16.4 |
| Retained earnings | -9.0 | -8.0 | -10.9 | -10.2 | -8.6 | -7.8 | -9.5 | -8.8 |
| Other equity | 0.0 | 0.2 | -0.1 | -0.2 | -0.3 | -0.1 | -0.1 | -0.1 |
| Equity to parent | 14.7 | 15.4 | 15.9 | 16.6 | 18.0 | — | — | — |
| Non-controlling interests | 0.7 | 0.8 | 0.9 | 1.0 | 0.7 | — | — | — |
| Total equity | 15.4 | 16.2 | 16.8 | 17.5 | 18.8 | 18.8 | 19.9 | 20.6 |
| Book value per share (TWD) | 11.03 | 11.59 | 11.98 | 12.42 | 13.54 | 14.18 | 15.07 | 15.64 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.6 | -0.7 | -0.9 | 2.0 | -3.8 | -0.9 | -0.6 | -0.8 |
| Investing cash flow | -0.1 | 0.9 | -4.2 | -1.2 | 3.7 | 2.0 | 2.0 | -6.5 |
| Financing cash flow | -0.0 | -0.0 | -0.0 | -0.0 | -0.2 | -0.0 | -0.0 | 5.0 |
| FX effect | -0.0 | 0.0 | -0.0 | -0.0 | — | — | — | — |
| Net change in cash | -0.7 | 0.2 | -5.1 | 0.8 | -0.3 | 1.1 | 1.4 | -2.3 |
| Cash, beginning | 8.0 | 8.0 | 8.0 | 5.0 | 5.0 | 5.0 | 5.0 | 9.5 |
| Cash, ending | 2.3 | 3.0 | 2.8 | 8.0 | 7.2 | 7.5 | 6.4 | 5.0 |
Amounts in NT$100M (per-share items in NT$).
| Metric | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 2,213.20% | 2,795.89% | — | — | — | — | — | — |
| Debt ratio | 3.11% | 2.58% | 2.73% | 4.05% | 2.98% | 14.98% | 15.08% | 14.70% |
| Equity ratio | 96.89% | 97.42% | 97.27% | 95.95% | 97.02% | 85.02% | 84.92% | 85.30% |
| Equity multiplier | 1.03 | 1.03 | 1.03 | 1.04 | 1.03 | 1.18 | 1.18 | 1.17 |
| Metric | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Asset turnover (TTM revenue / avg. assets) | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Equity turnover | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Source: MOPS. For reference only; not investment advice.